EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-marker RT-PCR panel for detecting metastatic breast cancer



Multi-marker RT-PCR panel for detecting metastatic breast cancer



Official Gazette of the United States Patent & Trademark Office Patents 1232(2), Mar 14



A method of detecting the metastasis of primary breast cancer to a lymph node is provided, comprising detecting, in lymph node tissue, the presence of a nucleic acid of c-myc, PIP or keratin-19. The presence of any one of these nucleic acids in lymph node tissue is associated with metastatic breast cancer. The presence of one or more of these markers in lymph node tissue or other tissue indicates that cells from the primary tumor have migrated from the breast tissue to the lymph node or other tissue. Also provided is a method of predicting the histopathologic stage of a cancer in a patient without having to perform a histopathologic analysis, comprising detecting, in lymph node tissue from the patient, the presence of a nucleic acid of c-myc, the presence of a nucleic acid of c-myc being correlated with stage I cancer as determined by histopathology. Alternatively, the absence of a nucleic acid of PIP and the absence of a nucleic acid of keratin-19 are correlated with stage I cancer as determined by histopathology. In another embodiment, the presence of a nucleic acid of PIP is correlated with stages later than stage I cancer as determined by histopathology. Further, the presence of a nucleic acid of keratin-19 is correlated with stages later than stage I cancer as determined by histopathology. A method of predicting survival time of cancer patients is also provided, comprising detecting, in lymph node tissue from the patient, the presence of a nucleic acid of c-myc, PIP or keratin-19. The presence of a nucleic acid of any of c-myc, PIP or keratin-19 is correlated with a shorter average survival time compared with the presence of none of the nucleic acids.

(PDF 0-2 workdays service: $29.90)

Accession: 035349347

Download citation: RISBibTeXText



Related references

Individual risk assessment in bladder cancer patients based on a multi-marker panel. Journal of Cancer Research and Clinical Oncology 139(1): 49-56, 2013

Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet. Oncology 3(12): 719-727, 2002

CA-125 is not a useful marker in metastatic breast cancer. British Journal of Cancer 66(5): 875-876, 1992

The use of carbohydrate antigen (CA) 15-3 as a tumor marker in detecting breast cancer. Pakistan Journal of Biological Sciences 11(15): 1945-1948, 2008

Invasive cribriform breast carcinomas in patients with grade 1 and stage IIA (T2 N0 M0) breast cancer strongly express the v3 and v6, but not the v4 isoforms of the metastatic marker CD44. Neoplasma 55(3): 246-255, 2008

CA 15-3, ceruloplasmin and tissue polypeptide specific antigen as a tumour marker panel in breast cancer. East African Medical Journal 77(6): 291-294, 2003

Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion. Breast Care 7(2): 137-143, 2012

The breast cancer panel: a case-based discussion on the use of targeted therapies for primary and metastatic disease. Ons News 21(8 Suppl): 37-38, 2006

Breast cancer survival and immunohistochemical similarities between primary and metastatic sites, as a surrogate marker for the cancer self-seeding. International Journal of Biological Markers 27(2): E167-E168, 2013

C-myc as a predictive marker for chemotherapy in metastatic breast cancer. Clinical and Experimental Medicine 12(4): 217-223, 2013

The value of cd38 lymphocyte marker in metastatic breast cancer. Journal of Tumor Marker Oncology 5(3): 253, 1990

Inexpensive biosensor capable of detecting HER-2/NEU protein, a chemical marker for breast cancer. Abstracts of Papers American Chemical Society 225(1-2): CHED 167, 2003

Panel discussion: The future shape of hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Research and Treatment 80(Supplement 1): S27-S28, 2003

Evaluation of a panel of potential serum tumor markers in women with metastatic breast cancer entered on a prospective chemotherapy clinical trial A North Central cancer treatment group study. Tumor Biology 17(SUPPL 1): 12, 1996

Successful use of multi-detector row computed tomography for detecting contralateral breast cancer. Journal of Computer Assisted Tomography 35(1): 148-152, 2011